The Lucy Cavendish Life Sciences Community provides both funding for students and a longer-term reciprocal relationship.
The Lucy Cavendish Life Sciences Community, a collaboration of local life-science businesses, provides essential funds for STEMM students during their study and aims to build reciprocal, long-term relationships with STEMM students, the College and the wider university. This will help the community of businesses form the creation of a broader, more diverse mix of talented STEMM students for future recruitment and students will have better access to employment opportunities within the community.
Ultimately, this supportive collaboration will improve and enrich the mix of future employees in life sciences and encourage the brightest and the best whatever their background to work in the industry. It will benefit our businesses, the Cambridge life-science cluster and society as a whole.
The scheme also aims to support under-represented communities’ outreach, and the creation of a supportive life science community engagement programme with both the STEMM students and the College, delivering mentoring, advice, networking and internship opportunities.
With support from AstraZeneca, the college is developing a range of events, seminars and round table discussions on themes of mutual interest such as the future of recruitment and the latest research.
The College’s Programme Co-ordinator, supported by AstraZeneca, is developing a wide range of optional engagement activities including:
- Speed mentoring session for younger undergraduates (18 years+)
- Speed mentoring for mature/graduate students
- Project guidance one-to-one sessions for first year students
- Blog post competition and hot topic debate
- Research event
- Alumni events for those working in the life sciences sector
- Careers Days for prospective students – focus on Widening Participation
- Career workshops
- Round table discussion
- Annual dinner at College
- Summer garden party
The Lucy Cavendish Life Sciences Community STEMM Hardship Fund
The Hardship Fund is aimed at levelling the playing field for disadvantaged STEMM students – ensuring that they can continue to study, live up to their potential and get the most out of their time at Cambridge.
Given the College’s many years of supporting disadvantaged students, requests for support may include the following:
- Living expenses (extra help for food, rent and other bills)
- Travel and conference costs
- Books, equipment and other study materials
- Access to professional mental health support
- Travel costs for hospital appointments
- Special requests for appliances for disabled students
- Sport and social clubs – fees/ kit/ special arrangements for disabled students etc.
The Hardship Fund is crucial to a student body that is increasing significantly both in size and diversity.
Astrazeneca is a global pharmaceutical company with a major UK presence. Their purpose is to push the boundaries of science to deliver life-changing medicines and share this passion with the scientific, healthcare and business communities of the UK, with Cambridge being one of the most exciting bioscience hotspots in the world.
Abzena is a life sciences group that provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. Working with companies and academic groups all over the world, including most of the top 20 biopharmaceutical companies, Abzena supports the development and manufacture of better treatments for patients.
Babraham Research Campus
The Babraham Research Campus is one of the UK’s leading places to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the world leading discovery research of the Babraham Institute. The Campus is a dynamic environment within 430 acres of parkland, home to over 60 companies, 2,000 employees and 300 academic researchers. It is where discovery research and business come together with a shared scientific focus that accelerates innovation and strengthens links between academia and the commercial world.
PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes addressing a range of unmet diseases.
Alchemab identifies human's naturally occurring protective antibodies by mining the antibody repertoires of individuals who are resistant to or recovered from disease. They are developing the antibodies into therapeutic products for broader use in patients who lack this protective response and are suffering from hard-to-treat diseases.